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Introduction
Estrogen receptor -positive (ER+) breast cancer (BC) is commonly treated with anti-estrogens that target tumor-driving ER activity by either inhibiting ER directly (e.g., tamoxifen), or reducing estrogen levels through suppression of biosynthesis [e.g., aromatase inhibitors (AIs), such as letrozole]. While adjuvant anti-estrogen therapies have shown clinical benefit for the treatment of ER+ BC, ~30% of patients eventually experience disease recurrence. Recurrent disease is ultimately fatal in a majority of cases, as cancers can rapidly become refractory to standard therapies. The bulk of these recurrence events occur after the standard five-year adjuvant anti-estrogen treatment regimen (termed "late recurrence") (1-3). This lengthy time to recurrence suggests that ER+ BC cells undergo extensive periods of dormancy, defined as disease that is undetectable by conventional clinical follow-up techniques (e.g., PET/CT). Indeed, circulating tumor cells (CTCs) in blood and disseminated tumor cells (DTCs) as well as micrometastases in bone marrow are detectable in "diseasefree" BC patients after years of adjuvant anti-estrogen therapy (4, 5) . Thus, there is a need for development of more effective adjuvant therapeutics to either maintain this residual disease in a dormant asymptomatic state, or to eradicate it. Such therapeutic development has been hampered by a limited understanding of the biology underlying dormancy.
Several groups have developed preclinical models of cancer cell dormancy and identified mechanisms driving emergence from dormancy (6, 7) , with the intent to develop therapeutics to suppress tumor outgrowth.
We postulated that understanding mechanisms that allow cancers cells to survive/persist in a dormant state would lead to curative therapies (i.e., cancer elimination) rather than suppressive therapies (i.e., maintenance of dormancy). Moreover, reported dormancy models often utilize therapy-naïve contexts, while more clinically relevant models would include (neo)adjuvant therapies. Additionally, there is a dearth of in vivo models of dormancy in ER+ BC, a cancer in which dormancy is exceedingly clinically relevant due to the long latency of recurrences and the steady lifetime risk of recurrence (8) . Herein, we developed in vivo models of estrogen withdrawal (EW)-induced dormant ER+ BC to identify mechanisms of BC cell survival/persistence, reflecting the clinical scenario of patients on (neo)adjuvant AI therapy.
Materials and Methods

Cell culture and RNA interference
Parental cell lines (ATCC) were cultured in DMEM with 10% FBS. For hormone deprivation (HD) experiments, cells were cultured in phenol-red free DMEM containing 10% dextran/charcoal-stripped FBS ± 1 nM E2. Cells were stably transfected with lentiviral vectors encoding luciferase, GFP, shRNA targeting AMPK1/PRKAA1 or non-targeting control. Cells were transiently transfected with siRNA targeting AMPK1/PRKAA1, AMPK2/PRKAA2, and/or non-silencing control.
Tumor growth studies
Animal studies were approved by the Dartmouth College IACUC. Female NOD-scid/IL2R -/-(NSG) mice or Foxn1 nu /Foxn1 nu (nude; JNu) mice (3-4 wk) were ovariectomized (ovx) and orthotopically injected bilaterally with MCF-7, HCC-1428, HCC-1500, or MDA-MB-415 luciferase/GFP-expressing cells, or implanted with fragments of HCI-017 patient-derived xenograft (PDX; a gift from Alana Welm, Univ. of Utah). Mice were simultaneously implanted s.c. with a 17β-estradiol (E2) pellet as indicated. Tumor dimensions were measured twice weekly using calipers (volume = [length 2 x width]/2). Once tumors reached ~400 mm 3 , E2 pellets were removed [i.e., estrogen withdrawal (EW)] and mice were randomized to treatments. Vehicle or metformin (1 mg/mL) were administered via drinking water containing 4% sucrose. Once tumors completely regressed (i.e., not palpable) following EW, residual tumor burden was monitored by bioluminescence imaging. For drugs tested against dormant residual disease: tumor-bearing mice were treated with EW for 60-90 d to induce dormancy; baseline bioluminescence was measured on two consecutive days and averaged; animals were treated as indicated and bioluminescence was serially measured. For molecular analysis, tumors were harvested at the indicated time points, fixed in formalin, and paraffin-embedded (FFPE).
Statistical analyses
Cell growth data and immunohistochemical (IHC) scores were analyzed by t-test (for two-group experiments), or ANOVA (for experiments with more than two groups) followed by Bonferroni multiple comparison-adjusted posthoc testing between groups. Mathematical models used to analyze tumor volumes and bioluminescence are described in Supplemental Methods.
Additional details are provided in Supplemental Methods
Results
A subpopulation of ER+ BC cells survives extended periods of estrogen withdrawal in a dormant state
Laboratory mice have low circulating levels of estrogens, and ovx further reduces systemic estrogen levels (9) .
Human ER+/HER2-BC cells commonly require estrogen supplementation to form tumors in immunodeficient mice. Ovx NSG mice injected subcutaneously (s.c.) with MCF-7 cells and supplemented with E2 formed visible tumors within 3 wk. Mice injected with MCF-7 cells without E2 supplementation did not form palpable tumors within 10 wk; however, E2 supplementation at the 10-wk time point induced tumor formation ( Fig. S1 ). This indicates that a proportion of MCF-7 cells survive extended estrogen withdrawal (EW) in a non-palpable, dormant state while retaining tumorigenicity.
We then developed a platform for the preclinical study of dormancy in ER+ BC (Fig. 1A) . ER+/HER2-BC cell lines stably expressing luciferase (MCF-7, HCC-1428, HCC-1500, or MDA-MB-415) or HCI-017 PDX tumor fragments were orthotopically implanted in the mammary fat pads of ovx immunodeficient (NSG or nude) mice, and mice were supplemented with E2. E2-driven tumors were grown to ~400 mm 3 to allow for establishment of tumor microenvironment and vasculature. E2 was then withdrawn to mimic the EW induced by AI therapy in patients. EW caused rapid tumor regression to a non-palpable state in all (MCF-7, HCC-1500, Histological analysis of dormant tumor beds after 90 d of EW revealed involutional-type changes, decreased tumor cellularity, increased stromal fibrosis, and extracellular deposition of basement membrane when compared to E2-driven tumors at baseline ( Fig. 1E ). Previous investigations of cancer dormancy have led to the characterization of two non-mutually exclusive states: 1) population-level dormancy, where insufficient resources lead to a balance between tumor cell proliferation and death that prevents tumor outgrowth; 2) cellular dormancy, where cells are arrested in G 0 (10) . Proportions of Ki67-positive tumors cells were significantly decreased after 6 d (short-term) and 90 d (long-term) of EW compared to baseline (E2driven), indicating reduced proliferative rates typically associated with cellular dormancy (Figs. 1F and S3A); these data are consistent with the reduced rates of Ki67-positivity observed in residual human tumors following 3 months of neoadjuvant AI therapy (11) . Low proportions of apoptotic cells were detected in tumors acquired at baseline and after 90 d of EW, while significantly increased apoptosis after short-term EW was observed only in MCF-7 tumors (Figs. 1G and S3B). As these dormant tumor cells can persist for >1 yr and only infrequently regrow palpable estrogen-independent tumors ( Fig. 1D ), population-level dormancy may also be occurring. Dormant tumor cells maintained variable degrees of ER positivity and frequent tumorigenic response to estrogen re-challenge (Figs. S2F-H and S3C-D). Consistent with the variability in ER levels, we found that dormant MCF-7 tumor cells were enriched for the CD24 low /CD44 high cancer stem cell phenotype (Fig. 1H) ; this reflects the ER-low phenotype of stem cells derived from human ER+ tumors (12) . Although DTCs and CTCs are frequently ER-in patients with primary ER+ breast tumors, recurrent tumors and metastases typically have ER concordance with primary tumors (13) (14) (15) , implying that ER-low cancer cells can give rise to ER+ tumors. Targets' were also significantly altered in dormant tumors. In a separate experiment with MCF-7 tumors harvested at similar time points from NSG mice, we digitally quantified transcripts from 770 genes using the NanoString PanCancer Pathways platform (Table S1 ). PRKAA2 mRNA, which encodes the 2 catalytic subunit of AMPK, was upregulated in dormant tumors, but not acutely EW tumors, compared to baseline in all three experiments (Figs. 2B and S5).
Dormant ER+ BC cells exhibit upregulated AMPK levels and consequent metabolic activities
AMPK is a cellular energy sensor that promotes catabolism in response to high AMP:ATP ratios or other stress signals. AMPK has a diverse range of cellular activities including, but not limited to, direct and indirect inhibition of mechanistic target of rapamycin complex 1 (mTORC1), induction of autophagy, induction of mitochondrial biogenesis and function through activation of peroxisome proliferator-activated receptor- coactivator-1 (PGC-1) and subsequent transcriptional signaling, and regulation of fatty acid metabolism through inhibitory phosphorylation of acetyl-CoA carboxylase (ACC) (16) . IHC analysis showed increased AMPK2 levels in dormant MCF-7, HCC-1428, and HCC-1500 tumor cells compared to E2-driven tumors (Figs. 2C and S6). P-ACC Ser79 , a marker of AMPK stimulation of fatty acid -oxidation (FAO), was increased in dormant tumor cells compared to E2-driven or acutely EW tumors in 3/4 xenograft models, demonstrating increased AMPK activity in dormant tumor cells (Figs. 2D and S6). In contrast, mTORC1 activity was not suppressed: dormant tumor cells exhibited elevated levels of P-S6, a downstream marker of mTORC1 activity, compared to E2-driven tumors (Fig. S7 ).
Neoadjuvant treatment with anti-estrogens frequently induces tumor regression but not pathologic complete response in post-menopausal women with early-stage ER+ breast cancer (17) . To determine whether residual tumor cells following anti-estrogen therapy exhibit alterations in markers of FAO, we evaluated transcriptional profiles of tumor specimens acquired at baseline and after neoadjuvant treatment from three patient cohorts. We derived a 992-gene expression signature of FAO inhibition using transcriptional profiles from MCF-7 cells treated +/-the CPT1 inhibitor etomoxir, which blocks FAO; this signature was used to generate an 'etomoxir t-statistic' for each tumor specimen, where the additive inverse is inferred to reflect FAO activation. In the GSE20181 cohort, patients were treated with neoadjuvant AI therapy with letrozole, and tumor specimens were serially obtained at baseline, Day 10-14, and Day 90 (18) . Tumors showed transcriptional profiles reflecting increased FAO on Day 90, but not Day 10-14, compared to baseline ( Fig. 2E) .
Similar results were observed in the GSE71791 cohort of patients treated with the anti-estrogen fulvestrant for 28 d (19) . The GSE111563 cohort contained patients treated with neoadjuvant letrozole for 4-45 months who experienced >40% decrease in tumor size within 4 mo; tumors were biopsied after 13-120 d of letrozole, and those with tumor progression or an increase in mRNA markers of cell proliferation (in the 13-to-120-day biopsy) were classified as "acquired resistant," while the remainder were classified as "dormant" (17) . "Dormant" tumors showed transcriptional profiles of FAO activation, while "acquired resistant" tumors did not ( Fig. 2E ).
Gene Ontology annotations for 77 of 992 genes in the etomoxir signature included "Cell Proliferation" or "Cell Cycle," so t-statistics were also generated for each tumor using the remaining 915 genes to minimize the contribution of proliferated-related transcripts; similar results were observed ( Fig. S8 ), indicating that tumor cells that persist during anti-estrogen treatment exhibit transcriptional profiles reflecting increased FAO.
If AMPK-directed energy metabolism is increased in dormant tumor cells, then mitochondrial content, cellular respiration, and FAO enzymes may be increased in parallel. Indeed, mitochondria-encoded mRNA levels were increased in dormant MCF-7 tumors compared to E2-driven and acutely EW tumors ( Fig. S9A ).
Morphological assessment revealed increased numbers of mitochondria and mitochondrial elongation in dormant tumors (Figs. 2F and S9B/C), indicative of increased levels and activity of mitochondria (20) . Dormant tumors showed increased levels of CTP1, which is the rate-limiting enzyme in mitochondrial FAO, compared to E2-driven tumors (Figs. 2G and S9D). These data collectively suggest that dormant tumor cells exhibit enhanced respiration and FAO. Since AMPK2 is involved in oxidative metabolism and required for efficient FAO (21), we tested whether the HD-induced increases in respiration were driven by AMPK. Using siRNA against either AMPK1 (PRKAA1) or AMPK2 (PRKAA2) alone was insufficient to mitigate AMPK activity (data not shown). Dual knockdown of both AMPK1/2 ablated AMPK activity (assessed by P-ACC loss) and reduced basal OCR and ATP production in ER+ BC cells under both HD and E2-stimulated conditions ( Fig. S10 ), indicating the importance of AMPK in controlling oxidative metabolism.
AMPK promotes mitochondrial biogenesis and FAO in dormant tumor cells
Since dormant tumor cells exhibited transcriptional changes reflecting increased FAO ( Fig. 2A ), which is a major output of AMPK activity, we tested the role of FAO in HD-induced changes in oxidative metabolism.
Treatment with etomoxir completely blocked HD-induced increases in basal OCR, spare capacity, and ATP production in vitro ( Fig. 3H-J) . These results suggest that, under HD conditions, AMPK activation drives metabolic adaptation to an increased oxidative state, primarily as a result of increased FAO.
AMPK activity and fatty acid oxidation are essential for tumor cell survival following estrogen withdrawal
Since AMPK-directed mitochondrial respiration and FAO are increased following HD in vitro, we next tested the roles of these pathways in cancer cell persistence and growth. Genetic inhibition of AMPK1/2 using siRNA significantly decreased MCF-7 cell number in HD conditions but not in the presence of E2 (Fig. 4A ). Treatment with the AMPK-inhibiting compound dorsomorphin significantly decreased growth of 6/6 ER+ BC cell lines in HD and E2-stimulated conditions ( Fig. 4B and data not shown).
In mice bearing dormant MCF-7/luciferase tumors (following 90 d of EW), "late" treatment with dorsomorphin rapidly decreased residual tumor cell number within 4 d (measured by bioluminescence imaging), suggesting induction of tumor cell death (Fig. 4C/D) . Statistical comparison of rates of regression (i.e., rate difference) of residual disease (i.e., bioluminescence) between treatment groups showed that dorsomorphin had a significant effect compared to vehicle control (p-value RD =0.001). Following cessation of dorsomorphin treatment after 25 d, bioluminescence remained suppressed, indicating that A) the effects of dorsomorphin were durable, and B) luciferase expression/activity was not directly impeded by drug treatment.
Dorsomorphin decreased P-ACC Ser79 IHC staining of tumor cells, confirming that AMPK activity was blocked ( Fig. 4E ). Since phosphorylation at Ser-79 inhibits ACC activity, which in turn promotes FAO (22) , these data suggest that A) FAO was consequently inhibited by dorsomorphin, and B) AMPK activity, possibly by increasing FAO, is essential for survival of dormant ER+ breast tumor cells.
Ranolazine is FDA-approved for angina treatment and inhibits FAO. Thus, we tested whether ranolazine was effective for targeting of dormant ER+ breast tumor cells. "Late" treatment (as in Fig. 4C To test whether inhibition of FAO is effective when administered concurrently with EW, mice bearing E2-driven MCF-7 or HCC-1428 tumors were treated "early" (as in Fig. 4C ) for 14 d with EW +/-one of three FAO inhibitors [ranolazine, etomoxir, or perhexiline, the latter two of which inhibit CPT1 (23-25)], followed by continued EW alone. All three FAO inhibitors hastened EW-induced tumor regression in one or both tumor models ( Fig. S11 ) measured by both the rate of change in tumor volume (p-value RD ) and the proportion of change in tumor volume with respect to baseline volume (i.e., long-term treatment effect; p-value LT ). We also tested whether "early" or "late" ranolazine treatment affects tumor re-growth potential, which indirectly reflects residual tumor cell burden. Mice pre-treated "early" with EW +/-14 d of ranolazine that achieved complete tumor regressions (from Fig. S11A ), and mice pre-treated with EW for 90 d followed by "late" ranolazine for 7 d, were re-challenged with E2. Both "early" and "late" ranolazine significantly delayed tumor recurrence compared to vehicle control ( Fig. 4H/I) . These data indicate that short-term FAO inhibition enhances the effects of EW on tumor regression and suppresses tumor regrowth.
AMPK activation via metformin enhances the survival of ER+ residual disease during estrogen withdrawal
Since activation of FAO is a downstream effect of AMPK signaling, we sought to test the effects of pharmacologic AMPK activation on ER+ breast cancer cells. Metformin is an oral anti-hyperglycemic drug widely prescribed for the treatment of diabetes mellitus type 2. Although the mechanism by which metformin exerts anti-diabetic effects remains controversial and is likely multi-faceted, it is generally accepted that a main cellular consequence of metformin is activation of AMPK to modulate metabolic and lipid signaling (26) . Based primarily on A) epidemiologic evidence suggesting that metformin has anti-cancer properties in diabetic patients (27) , and B) preclinical data showing that metformin slows cancer cell and tumor growth (28, 29) , metformin is being heavily tested clinically for the treatment of a variety of cancer types in non-diabetic patients. Reports have thus far yielded conflicting results (30) (31) (32) (33) , which may be due in part to the variable pharmacokinetic properties and therapeutic effects of metformin in humans (34) . Conflictingly, data also support a tumor-promoting role for AMPK. P-ACC levels in primary tumors are associated with shorter overall survival in patients with non-small cell lung cancer and head and neck squamous cell carcinomas (35, 36) .
AMPK activation is associated with disease recurrence in prostate cancer, the mechanism of which was linked to PGC-1 signaling and subsequent mitochondrial biogenesis and function (37) . Our data indicated that AMPK-directed metabolism drives survival of residual ER+ breast tumor cells during EW (Fig. 4 ). Thus, we tested whether AMPK activation via metformin affects growth of ER+ BC cells and tumors during HD and EW, respectively.
Little is known about the concentrations of metformin that reach cancerous tissues in humans. In vitro evidence identifying metformin as an effective anti-cancer agent was generated with supra-pharmacologic concentrations of metformin (5-50 mM); achievable plasma concentrations in humans are in the low micromolar range. Thus, we first performed a pharmacokinetic study in mice to obtain an understanding of achievable tissue concentrations of metformin. Mice were administered ~5 mg/d metformin via drinking water for 6 wk. Resultant steady-state plasma concentrations of metformin were 4.27 ± 1.19 M (mean ± SD; Fig.   S12A ), which are in agreement with the preclinical findings of Dowling et al. and reflect human steady-state plasma concentrations of 0.08-6.5 M (38). This dose in mice elicited growth-inhibitory effects on MCF-7 xenografts (p-value RD <0.001) and activated AMPK in tumor tissues ( Fig. S12B/C ). Metformin concentrations in tissues (tumor, liver, muscle) range from 0.47 to 1.14 M (Fig. S12A ). In parallel, our studies in cultured MCF-7 cells revealed that treatment with 1 mM metformin-the lowest dose that maximally induced AMPK activation- In vitro, treatment with 1 mM metformin significantly rescued growth of 6/6 ER+ BC cell lines in HD conditions for ≥3 wk (Fig. 5A) . The ability of metformin to rescue such growth was ablated upon siRNA-induced knockdown of AMPK1/2, suggesting that metformin rescues growth in HD conditions via AMPK activation ( Fig. 5B) .
To test the effects of metformin on ER+ breast tumor cell persistence during EW, we treated mice bearing E2-driven tumors with EW ± metformin and monitored tumor volume ( Fig. 5C ); this is analogous to the clinical scenario of treatment with AI therapy ± metformin. In MCF-7, HCI-017, HCC-1428, and MDA-MB-415 models, concurrent treatment with metformin slowed EW-induced tumor regression compared to EW/placebo controls (all log-rank p<0.05; Figs. 5D and S13-14). Metformin did not significantly alter levels of serum insulin, serum free fatty acids, or blood glucose (Fig. S15 ). Increased P-ACC staining was observed in tumors obtained from mice treated with metformin for 6-12 d (Figs. 5E and S16). These data indicate that metformin enhances ER+ breast tumor cell persistence and AMPK activation during EW.
Interestingly, metformin did not rescue HCC-1500 tumors from regression induced by EW in vivo, or HCC-1500 cells from HD in vitro (Fig. S17A/B ). HCC-1500 cells have relatively high levels of AMPK2 protein and AMPK activity compared to MDA-MB-415, HCC-1428, and MCF-7 cells (Fig. S17C ). Furthermore, metformin did not alter P-ACC levels in HCC-1500 cells in vitro or EW-treated tumors in vivo (Fig. S17D/E); these observations explain in part why metformin did not enhance cell persistence upon HD/EW in this model, and emphasize the dependence upon AMPK activation for metformin effects in ER+ BC cells and tumors.
Fatty acid oxidation sustains ER+ breast cancer cells during estrogen deprivation
In E2-stimulated conditions, 24 h of treatment with metformin enhanced markers of glucose and fatty acid metabolism, cell cycle inhibition, and autophagy. In HD conditions over a time-course of 15 d, metformin enhanced expression of FAO enzymes and mitochondrial respiratory proteins (Fig. 6A) . Treatment with the FAO inhibitor etomoxir ablated the ability of metformin to sustain growth of HCC-1428 and MCF-7 cells in HD conditions ( Fig. 6B ), suggesting that metformin drives FAO to promote hormone-independent growth/persistence.
Since FAO sustains ER+ BC cells during HD in vitro, and adipocytes can acts as an energy source for
tumor cells through provision of fatty acids (39), we tested whether exogenous fatty acid elicits similar effects.
Despite enhancing MCF-7 cell growth in HD conditions (Fig. 6C) , treatment with free oleic fatty acid did not alter basal OCR, spare capacity, or ATP production after 15 d of HD, possibly because HD cells had saturated FAO or respiratory activity ( Fig. 6D-F) . Interestingly, oleic acid treatment increased basal OCR, ATP production, and levels of P-ACC and PGC-1 in E2-stimulated conditions (Fig. 6D-G) , suggesting that cancer cells can respond to increased fatty acid abundance (i.e., fuel) by increasing FAO (i.e., catabolism).
In mice bearing E2-driven MCF-7 tumors, pre-conditioning with a high-fat diet slowed EW-induced tumor regression (p-value RD <0.001; Fig. S18 ), as was observed with metformin (Figs. 5D and S13-14). While pre-conditioning with a low-fat diet provided EW-induced complete tumor regression in 100% (20/20) of cases within 6 wk, a high-fat diet allowed complete regression in only 38% (7/19) of cases within 12 wk (log-rank p<0.0001; Fig. 6H ). IHC analysis of tumor specimens suggested that differences in tumor response to EW were not due to dietary pre-conditioning effects on tumor cell proliferation (Ki67), but rather due to high-fat dietinduced increases in tumor cell FAO (i.e., increased CPT1 and P-ACC) at the start of EW on Day 0 (Figs. 6I-K and S19).
Discussion
Herein, we described the development of preclinical models of dormancy in ER+ BC. In an EW state, as would occur in patients treated with AI therapy, small proportions of ER+ breast tumor cells persisted in a growth- As an initial investigation into mechanisms driving the persistence of dormant tumor cells, we evaluated orthotopic xenograft models of human ER+ BC in immunodeficient mice; potential translational limitations of these models are the mammary adipose tissue microenvironment, and the microenvironment of regressed tumors. In humans, ~30% of ER+/HER2-BC recurrences observed within 10 yr of follow-up occur locally in the ipsilateral breast, while the majority of recurrences occur in distant metastatic sites (1). Determining whether similar mechanisms of dormancy and therapeutic sensitivity occur in cancer cells in mammary adipose tissue vs. distant sites of metastasis (e.g., bone, liver, lung, brain) will require the generation of organ-specific models of metastatic ER+ BC. We established small E2-driven tumors (~9 mm in diameter) and induced regression by EW to study persistent dormant cancer cells; this paradigm reflects the clinic scenario of occult residual/micrometastatic disease in patients treated with AI therapy that is below the limit of detection (~7 mm) of PET/CT (40) . The extracellular microenvironment of regressed tumors may differ from that of isolated DTCs, which could also affect dormancy signalling and drug sensitivity.
How dormant tumor cells interact with and respond to a functional (human) immune system may provide clues to improve therapy; however, the model systems used herein are immunodeficient. Emerging evidence suggests that transcriptional programs that control dormancy (i.e., growth suppression, angiogenic switch) might also coordinate an immune-evasive phenotype (41) , offering a potential therapeutic strategy to sensitize dormant cells to immunotherapies. Work by Malladi et al. showed that latent metastatic human cancer cells implanted in nude mice were maintained in a slow-cycling dormant state by autocrine WNT inhibition, which caused downregulation of signals required for natural killer cell-mediated clearance (42) .
Future studies involving animal models with humanized immune systems would aid in investigating the roles of immune evasion and surveillance in cancer dormancy.
Precision medicine is based upon the premise that using the right treatment, for the right patient, at the right time will maximize therapeutic index. However, 'time' (i.e., stage during progression of a disease) is not always considered during drug development. History provides examples of FDA-approved drugs that showed efficacy against (clinically evident) recurrent/metastatic solid tumors, but which failed to increase recurrencefree survival when tested in adjuvant settings (in patients with no evidence of residual disease) (43) (44) (45) (46) (47) (48) (49) . Such disparate findings between adjuvant and recurrent/metastatic settings may be partly attributable to biological differences: the biology and microenvironments (e.g., vasculature, stroma, extracellular matrix, inflammation, hypoxia) of established tumors likely differ substantially from those of dormant tumor cells; thus, drug sensitivity may also differ. Drug treatments are generally most beneficial when tumor burden is low [i.e., adjuvant setting following surgical resection of measurable tumor(s)], so the typical drug development paradigm has been to demonstrate clinical efficacy against overt recurrent/metastatic disease, then clinically test the drug in the adjuvant setting; the gap in this paradigm is preclinical testing of the drug in an "adjuvant setting." Herein, we present a preclinical platform to test therapeutic strategies that target dormant residual disease in the background of EW therapy for ER+ BC. It is hoped that such preclinical testing would become standard practice prior to initiation of a costly adjuvant clinical trial that will take years to yield results, particularly with ER+ BC due to long durations of dormancy and times to recurrence.
Based on preclinical molecular analyses of dormant vs. growing ER+ breast tumors, we identified AMPK activation as a driver of dormant cancer cell persistence, which led to evaluation of metformin.
Preclinical studies have shown that metformin elicits anti-proliferative effects in a variety of cancer cell lines in vitro and in vivo, which is thought to occur partly by suppression of mTORC1 signaling (26, 28, 29) . Conversely, metformin slowed EW-induced regression of ER+ breast tumors and promoted persistence/growth of ER+ BC cells during HD (Figs. 5A/D and S13-14), suggesting that AMPK activation promotes ER+ BC cell survival during the stress of EW. In line with these findings, AMPK has been shown to promote cancer cell survival during stress induced by nutrient starvation (16, 50) . Our collective findings highlight 'timing' as an important consideration in precision medicine and therapeutic development. Extrapolating these findings to the human condition, metformin use concurrent with anti-estrogen therapy may promote the survival of residual endocrinesensitive ER+ BC cells, which could increase risk of recurrence. Thus, the timing of metformin therapy in patients with ER+ BC may impact clinical benefit, and timing needs to be considered when interpreting clinical trial results. Although AMPK inhibition reduced ER+ breast tumor cell burden under EW conditions ( Fig. 4A-D) , this may be a difficult therapeutic strategy to develop clinically because an AMPK inhibitor could also promote tumor growth. Focusing on the metabolic alterations induced by AMPK activation, we found that dormant ER+ breast tumor cells were dependent upon FAO, which may be a more practical therapeutic target. Indeed, FAO inhibitors are clinically approved for angina treatment and could be repurposed as cancer therapeutics. "Early" treatment was EW + ranolazine (14 d) administered to tumor-bearing mice, followed by 97 d of EW alone; after 90 d of EW, "Late" treatment was EW + ranolazine (7 d) administered to mice with completely regressed xenografts, followed by 7 d of EW alone. Mice without palpable tumors were then re-challenged with E2, and tumor recurrence was detected by palpation. Recurrence-free survival curves were compared to vehicle group by log-rank test. In (A/B/E), *p≤0.05 by t-test compared to control unless indicated. n.s.-not significant. In (D/F/G), bioluminescence signal values were compared by non-linear effect modeling. 
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